about
A BAR domain-mediated autoinhibitory mechanism for RhoGAPs of the GRAF familyPreclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s DiseaseThe effect of intracellular molybdenum in Hydrogenophaga pseudoflava on the crystallographic structure of the seleno-molybdo-iron-sulfur flavoenzyme carbon monoxide dehydrogenaseCatalysis at a dinuclear [CuSMo(==O)OH] cluster in a CO dehydrogenase resolved at 1.1-A resolution.The C2 domain of SynGAP is essential for stimulation of the Rap GTPase reactionA restricted spectrum of NRAS mutations causes Noonan syndromeStabilizing a weak binding state for effectors in the human ras protein by cyclen complexesArl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargoCrystal structure of a carbon monoxide dehydrogenase reveals a [Ni-4Fe-5S] clusterOptimization of the All-D Peptide D3 for Aβ Oligomer EliminationPurification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR SpectroscopyStructural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous TrifluoroethanolStructural Characterization of Fibrils from Recombinant Human Islet Amyloid Polypeptide by Solid-State NMR: The Central FGAILS Segment Is Part of the β-Sheet CoreCompetitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and ToxicityThe role of Se, Mo and Fe in the structure and function of carbon monoxide dehydrogenase.Engineered aggregation inhibitor fusion for production of highly amyloidogenic human islet amyloid polypeptide.Liposome reconstitution and modulation of recombinant prenylated human Rac1 by GEFs, GDI1 and Pak1.QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomersPyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation.Role of centrosomal adaptor proteins of the TACC family in the regulation of microtubule dynamics during mitotic cell division.Rho-kinase: regulation, (dys)function, and inhibition.IQGAP1 Interaction with RHO Family Proteins Revisited: KINETIC AND EQUILIBRIUM EVIDENCE FOR MULTIPLE DISTINCT BINDING SITES.Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.β-Hairpin of Islet Amyloid Polypeptide Bound to an Aggregation InhibitorThe centrosomal adaptor TACC3 and the microtubule polymerase chTOG interact via defined C-terminal subdomains in an Aurora-A kinase-independent manner.Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.Opposed Effects of Dityrosine Formation in Soluble and Aggregated α-Synuclein on Fibril Growth.Correction: Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity.Mechanistic insights into specificity, activity, and regulatory elements of the regulator of G-protein signaling (RGS)-containing Rho-specific guanine nucleotide exchange factors (GEFs) p115, PDZ-RhoGEF (PRG), and leukemia-associated RhoGEF (LARG).Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation.A novel binuclear [CuSMo] cluster at the active site of carbon monoxide dehydrogenase: characterization by X-ray absorption spectroscopy.Impact of subunit linkages in an engineered homodimeric binding protein to α-synuclein.Analysis of the Bin1 SH3 interaction with peptides derived from the hepatitis C virus protein NS5A and c-Myc reveals that NS5A can competitively displace c-Myc in vitro.Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGap interaction.Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species.Structural analysis of the pyroglutamate-modified isoform of the Alzheimer's disease-related amyloid-β using NMR spectroscopy.The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.Fibril structure of amyloid-β(1-42) by cryo-electron microscopy.Surprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs.Optimization of d-Peptides for Aβ Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic Aβ Oligomers.
P50
Q24309329-146A154A-41A6-46AA-A616-A439AA368640Q27305174-7FA62029-F0BA-4F27-98E5-BB885B4906A9Q27626821-7681323A-FA71-4E41-B6AE-F570825FEE17Q27640148-5EFFD290-F1C9-42D5-98EF-2197620FDEFFQ27650014-B3E72660-E94A-46B4-8210-E333E1C105DFQ27658480-68A8FFD6-E47C-4900-9F58-5094269D0117Q27660611-D4797A6E-EA0F-4DF4-9679-5F1C92167400Q27675096-789959D5-C3B1-4AD4-90EF-7F33F9521E15Q28213323-F1ECF5A9-FEB9-45F2-A6BF-12D547823575Q28275093-57875BBD-4739-4562-B05A-302791481476Q28550062-65389ABC-3672-451E-B222-2A9CB7685FCEQ28551142-CC2E8F29-6CF4-45E7-9AFD-8F5A0006BA5BQ28553950-6DAFFECB-8107-480F-B6E2-87A40C8DF5D2Q28601353-1009C847-95E8-4272-9409-D1C676FBDC08Q34081451-C02F01E8-AEE5-4FDF-B4E6-6FB7EF878075Q35187998-4415E47B-CFAC-445B-BA83-BAA08F6007EEQ35205434-B058C50C-D946-4CDE-9ADC-B0B8BD4A5BD5Q36099501-28DB0E16-607E-4214-B519-8B9BC2DE7FA8Q36356545-30D94E28-3976-448F-B79A-D76EF9B03252Q38115923-ED2A70F8-829A-4427-82C8-16FE0B0C42E5Q38129373-FBF2DF60-1704-41B1-BFAE-3388EE9FD37CQ39213624-4F14E00D-429D-4474-ACF0-3DB4E53C43C8Q39260997-517FCED2-8B34-46CC-B06A-F6466B3B7440Q41117781-404DAE20-B05B-4E13-9901-698CFA317E68Q41848433-0EA01BE6-BBE1-436D-943A-1ED7DBF5588AQ42049635-35D6B9BF-89C2-4C90-B209-A3941E1BE671Q42375123-556BF7DF-9DA0-499C-9374-62C5EF9E50CFQ42424949-1E8833A4-1F5A-4820-876F-B5D5A910B2A2Q42733267-C8316A83-4FE2-4966-B841-C4FD646F7246Q43227392-7DD040CF-1FB0-43D8-96EE-DB6CD1DCEB79Q44270925-70582C61-1E46-4129-9B92-9BC77EFAAEDDQ44675901-FA870023-F392-4E3C-855B-20E9B4BB9BE5Q45971698-016F7823-80A3-473D-8608-61DF24486C86Q46422384-213A47F2-F78A-4B0E-A22D-A651D7894EF9Q46540524-A15E2874-A2D4-4EE5-98FB-BAF2708A73F0Q46902534-B858C54A-BBDC-4B7C-A586-5DE7C3842FE9Q47144123-B49F408B-2832-4EF8-94E2-77A1913B5046Q47838176-5E76EB28-108E-4442-BE64-543BA0CC411EQ47920093-F4B132E7-CD68-4DCB-9D3E-B078DBF60FACQ48327869-41CCDC05-FF98-429C-AC88-367D40CDC300
P50
description
biochemicus
@nl
hulumtues
@sq
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Lothar Gremer
@ast
Lothar Gremer
@de
Lothar Gremer
@en
Lothar Gremer
@es
Lothar Gremer
@fr
Lothar Gremer
@nl
Lothar Gremer
@sl
type
label
Lothar Gremer
@ast
Lothar Gremer
@de
Lothar Gremer
@en
Lothar Gremer
@es
Lothar Gremer
@fr
Lothar Gremer
@nl
Lothar Gremer
@sl
prefLabel
Lothar Gremer
@ast
Lothar Gremer
@de
Lothar Gremer
@en
Lothar Gremer
@es
Lothar Gremer
@fr
Lothar Gremer
@nl
Lothar Gremer
@sl
P227
P1053
H-9128-2013
P1153
6602975391
P21
P214
9964151052056633530002
P227
1143554108
P31
P3829
P496
0000-0001-7065-5027
P569
2000-01-01T00:00:00Z
P734
P735
P7859
viaf-9964151052056633530002